Viewing Study NCT06384261


Ignite Creation Date: 2025-12-24 @ 12:18 PM
Ignite Modification Date: 2025-12-27 @ 9:40 PM
Study NCT ID: NCT06384261
Status: RECRUITING
Last Update Posted: 2025-09-10
First Post: 2024-04-18
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
Sponsor: OncoVerity, Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module